HD-OPM Archive
Topics › Brain health & dementia

Two RCTs of simvastatin and atorvastatin in Alzheimer's: no slowing, no worsening

Louis Nervegna · Oct 14, 2025 · ♥ 6 reactions · 0 comments · original Facebook post
Brain health & dementiaStatins
↻ This is a repost. The main version (highest ranked) is Two RCTs found statins neither helped nor harmed Alzheimer's disease progression · Jun 23, 2025.
AI summary & key facts

Louis says claims that statins worsen Alzheimer's are nonsense, citing two randomized trials of statins as Alzheimer's treatment, both neutral. The simvastatin trial (406 people, 18 months) lowered lipids with no change in ADAS-Cog and no increase in adverse events; a second trial tested atorvastatin on top of donepezil in mild-to-moderate Alzheimer's.

Claims that statins make Alzheimer’s worse are nonsense.

Research cited

There have been two randomized controlled trials testing statins as a treatment for Alzheimer’s Disease.

One used simvastatin, and the other used atorvastatin.

Both trials showed a neutral result. The statins did not slow the progression of the disease, nor did they worsen it.

—— Simvastatin trial ——

Publication:

Paper · Neurology · 2011A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer diseaseneurology.org

Quoted:

“This randomized, double-blind, placebo-controlled trial of simvastatin was conducted in individuals with mild to moderate AD and normal lipid levels. Participants were randomly assigned to receive simvastatin, 20 mg/day, for 6 weeks then 40 mg per day for the remainder of 18 months or identical placebo. The primary outcome was the rate of change in the Alzheimer's Disease Assessment Scale–cognitive portion (ADAS-Cog).”

“A total of 406 individuals were randomized: 204 to simvastatin and 202 to placebo. Simvastatin lowered lipid levels but had no effect on change in ADAS-Cog score or the secondary outcome measures. There was no evidence of increased adverse events with simvastatin treatment.”

—— Atorvastatin trial ——

Publication:

Paper · Neurology · 2010Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe.Conclusion: In this large-scale randomized controlled trial evaluating statin therapy as a treatment for mild to moderate Alzheimer disease, atorvastatin was not associated with significant clinical benefit over 72 weeks. This treatment was generally well-tolerated without unexpected adverse events.neurology.org

Quoted:

“This was an international, multicenter, double-blind, randomized, parallel-group study. Subjects had mild to moderate probable AD (Mini-Mental State Examination score 13–25), were aged 50–90 years, and were taking donepezil 10 mg daily for ≥3 months prior to screening. Entry low-density lipoprotein cholesterol levels (LDL-C) were >95 and <195 mg/dL. Patients were randomized to atorvastatin 80 mg/day or placebo for 72 weeks followed by a double-blind, 8-week atorvastatin withdrawal phase. Coprimary endpoints were changes in cognition (Alzheimer's Disease Assessment Scale-Cognitive Subscale [ADAS-Cog]) and global function (Alzheimer's Disease Cooperative Study Clinical Global Impression of Change [ADCS-CGIC]) at 72 weeks.”

“A total of 640 patients were randomized in the study. There were no significant differences in the coprimary endpoints of ADAS-cog or ADCS-CGIC or the secondary endpoints. Atorvastatin was generally well-tolerated.”

————-

#statinsHD #dementiaHD #alzheimersHD #statinsdementiaHD #ldldementiaHD #atorvastatinHD #simvastatinHD

← newer: Green tea extract improved muscle insulin sensitivity in obeolder: PREVENTABLE: atorvastatin 40 mg vs placebo up to 5 years in →